CD58 could be a leukemic marker in patients with relapsed/refractory B-cell acute lymphoblastic leukemia after multiline therapies
Am J Clin Pathol. 2025 Apr 20:aqae166. doi: 10.1093/ajcp/aqae166. Online ahead of print. ABSTRACT OBJECTIVES: As a marker of minimal residual disease in B-cell acute …